Zhihui Zhang

Dr. Zhihui Zhang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2020 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
PDF file
YZYang Zhou
Yang Zhou
ZZZhihui Zhang
Zhihui Zhang
SLShaomang Lin
Shaomang Lin
JXJianbin Xiao
Jianbin Xiao
WAWenjia Ai
Wenjia Ai
QLQiang Li
Qiang Li
Purpose: To report the results of a network meta-analysis of randomized controlled trials (RCTs) comparing multiple endovascular treatments for de novo femoropopliteal lesions. Materials and Methods: The MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials databases were systematically searched on June 1, 2019, for prospective RCTs comparing 14 treatments [ie, atherectomy, brachytherapy, cryoplasty, cutting balloons, drug-coated balloons, bare nitinol stents, drug-eluting stents (DES), covered stents (CS), and combinations] in the treatment of de novo femoropopliteal lesions. Outcomes were technical success; binary restenosis and target lesion revascularization (TLR) at 6, 12, and/or 24 months; and all-cause mortality at 12 months. Ultimately, 53 articles reporting on 45 studies (91 study arms; 5565 patients) were selected. For the technical success outcome, all types of stents, all balloons, and all atherectomy devices were aggregated in stent, balloon, and atherectomy technology groups, respectively. Results: In terms of technical success for aggregated treatment types, stent technology was the most effective treatment and was better than balloon and atherectomy technologies. In terms of binary restenosis, DES was the most effective single treatment at the 6- and 12-month follow-up and CS at the 24-month follow-up. Both DES and CS were better than the majority of other single treatments, including balloon angioplasty, cutting balloon, cryoplasty, directional atherectomy, and bare nitinol stent during all follow-up periods. In terms of TLR, DES was the second most effective single treatment and the most effective single treatment at the 6- and 12-month follow-up intervals; CS was the most effective single treatment at the 24-month follow-up. Both DES and CS were better than the majority of other single treatments. The 12-month all-cause mortality of both DES and CS were similar to other treatments, whereas cryoplasty seemed to be the least effective treatment with regard to binary restenosis and TLR. Conclusion: Both DES and CS had substantial advantages in terms of restenosis and TLR in femoropopliteal lesions and were similar to aggregate stent technology in terms of technical success. DES performed better within 12 months after operation and CS at ~24 months, but neither had much advantage in terms of mortality. In contrast, cryoplasty seemed to be a less effective treatment.

1 October 2019 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
YZYang Zhou
Yang Zhou
SLShaomang Lin
Shaomang Lin
ZZZhihui Zhang
Zhihui Zhang
JXJianbin Xiao
Jianbin Xiao
WAWenjia Ai
Wenjia Ai
QLQiang Li
Qiang Li

23 October 2019 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
YZYang Zhou
Yang Zhou
ZZZhihui Zhang
Zhihui Zhang
SLShaomang Lin
Shaomang Lin
JXJianbin Xiao
Jianbin Xiao
WAWenjia Ai
Wenjia Ai
QLQiang Li
Qiang Li

2 March 2022 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
JXJianbin Xiao
Jianbin Xiao
SLShaomang Lin
Shaomang Lin
YZYang Zhou
Yang Zhou
WAWenjia Ai
Wenjia Ai
YLYangyong Li
Yangyong Li
ZZZhihui Zhang
Zhihui Zhang

1 January 2025 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
WAWenjia Ai
Wenjia Ai
FLFangfei Li
Fangfei Li
QYQilin Yang
Qilin Yang
JQJingluo Qiu
Jingluo Qiu
AZAiqiang Zhou
Aiqiang Zhou
ZZZhihui Zhang
Zhihui Zhang
Background: Identifying high‐risk patients with acute pulmonary embolism is vital for improving disease prognosis. However, current guidelines and research on risk factors are insufficient to meet clinical needs. This study was aimed at exploring novel risk factors to predict in‐hospital mortality. Methods: We utilized a patient cohort from the Medical Information Mart for Intensive Care Version IV (MIMIC‐IV) database as training cohort. Major analyses included screening risk factors for in‐hospital mortality, correlation analysis via smooth curve fitting, multivariate Cox regression, and subgroup analysis. The findings were further validated with our own institute patient cohort. Results: Among 1463 adult patients with acute pulmonary embolism in the MIMIC‐IV database, the overall in‐hospital mortality rate was 17.8%. A nonlinear correlation was observed between urine output and in‐hospital mortality. A urine discharge less than 0.85 mL/kg/h was used as the threshold and was negatively associated with the risk for in‐hospital death. Compared to patients with urine value < 0.5 mL/kg/h, the risk for in‐hospital mortality reduced by 36% and 48% in patients with urine values of 0.5–0.85 mL/kg/h and > 0.85 mL/kg/h, with the hazard ratios of 0.64 (0.47, 0.87) and 0.52 (0.38, 0.72), respectively. This association remained significant in the subgroup analysis after adjusting for age, gender, hypotension, and low oxygen saturation. Our validation patient cohort ( n = 151) further confirmed the strong association of the urine value with in‐hospital mortality and consistent cutoff value. Conclusion: Our study revealed a negative association of urine output with in‐hospital mortality in acute pulmonary embolism patients, with the optimal urine output being significantly higher than the value of other critical illnesses.

Verified
Journal Article
Open access
PDF file
JXJianbin Xiao
Jianbin Xiao
TQTao Qiu
Tao Qiu
HWHong Wang
Hong Wang
HZHongji Zha
Hongji Zha
JCJiayue Chen
Jiayue Chen
ZZZhihui Zhang
Zhihui Zhang
Abdominal aortic aneurysm (AAA) enlargement is a major risk factor for aneurysm rupture and the development of abdominal aneurysm dissection (AAD). However, reliable serum biomarkers for predicting AAD occurrence remain lacking. This study was designed to identify circulating serum markers capable of predicting AAA progression and AAD formation. Patients diagnosed with AAA or AAD at our institution between 2020 and 2025 were enrolled and corresponding clinical characteristics were analyzed. Peripheral blood levels of arachidonic acid (AA) and 12–HETE were measured using ELISA, and Alox12 mRNA expression was determined by quantitative real-time polymerase chain reaction (qRT-PCR). Candidate serum biomarkers associated with AAA enlargement and AAD development were investigated using a multi-modal approach integrating computed tomography (CT) images, serum metabolic profiles, and aneurysm wall tissue analyses. A total of 52 AAA patients and 42 AAA patients were included in the analysis. Elevated serum 12–HETE and TG levels were significantly associated with AAA enlargement and the occurrence of AAD, whereas AA levels showed no significant difference between groups. Dysregulated AA/12–HETE metabolism is an independent risk factor for aneurysmal enlargement in AAA and AAD, while 12–HETE and TG help to discriminate AAD from AAA.